An increased incidence of thrombosis, including pulmonary embolism, deep venous thrombosis, and arterial thrombosis, was observed in patients treated with XELJANZ in a large, ongoing post-marketing study. The Canadian Product Monograph (CPM) of XELJANZ/XELJANZ XR has recently been updated regarding the risks of thrombosis and the use of XELJANZ/XELJANZ XR.
Products affected
-
XELJANZ (tofacitinib), 5 mg and 10 mg tablets
-
XELJANZ XR (tofacitinib), 11 mg extended-release tablets
Background information
In a large, ongoing post-marketing study (Study A3921133), thrombosis, including pulmonary embolism, deep vein thrombosis and arterial thrombosis, was observed at an increased incidence in patients with rheumatoid arthritis. The study showed that rheumatoid arthritis patients aged 50 years or older with at least one cardiovascular (CV) risk factor had a higher rate of all-cause mortality, including sudden CV death, and thrombosis when a 10 mg twice daily dose of XELJANZ was used compared to those treated with XELJANZ 5 mg given twice a day or TNF blockers.
On
March 15, 2019, Health Canada announced that it was conducting a safety review after issues were discovered during this ongoing clinical trial. Health Canada has reviewed interim data from this study. To address this safety concern, Health Canada has worked with Pfizer Canada ULC to update the XELJANZ/XELJANZ XR Canadian Product Monograph (CPM). The increased risk of thrombosis has been included in the
Serious Warnings and Precautions Box of the XELJANZ/XELJANZ XR CPM. The
Adverse Reactions and
Consumer Information sections in the CPM have also been updated in relation to this issue.
XELJANZ/XELJANZ XR has received market authorization in Canada for the following indications:
Rheumatoid Arthritis
XELJANZ/XELJANZ XR, in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of rheumatoid arthritis (RA) in adult patients with moderately to severely active RA who have had an inadequate response to MTX. In cases of intolerance to MTX, physicians may consider the use of XELJANZ/XELJANZ XR as monotherapy.
Psoriatic Arthritis
XELJANZ, in combination with methotrexate (MTX) or another conventional synthetic disease-modifying antirheumatic drug (DMARD), is indicated for reducing the signs and symptoms of psoriatic arthritis (PsA) in adult patients with active PsA when the response to previous DMARD therapy has been inadequate. The use of XELJANZ in combination with biological disease-modifying anti-rheumatic drugs (bDMARDs) or potent immunosuppressants such as azathioprine and cyclosporine is not recommended.